Program
PF-07261271
A development code.
In Pfizer's pipeline, p40/TL1A bispecific
. Its studies are mostly in Inflammatory Bowel Diseases, led by Pfizer.
Furthest: phase 1, since Sep 7, 20221 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 10 open or running | phase 1since Sep 7, 2022 | Sep 7, 2022 | none ahead |
- Named in Pfizer’s own pipeline as
PF-07261271
, phase 2, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 7, 2022First study: phase 1 study in Inflammatory Bowel DiseasesFirst studyNCT05536440 · 35 enrolled · United States
TargetBeta
“p40/TL1A bispecific”the company's pipeline, read by Claude · source
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05536440Inflammatory Bowel Diseases · United States | 1 | Completed | Feb 29, 2024 | 35 |
How it is read
Names in the registry
- “PF-07261271”, 1 entry
Codes read as this program: PF07261271.
Conditions, from the studies’ own filings
- Inflammatory Bowel Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.